# reload+after+2024-01-22 19:45:25.163554
address1§830 Winter Street
city§Waltham
state§MA
zip§02451-1477
country§United States
phone§781 895 0600
website§https://www.immunogen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
fullTimeEmployees§277
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Mark Joseph Enyedy', 'age': 59, 'title': 'President, CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1284825, 'exercisedValue': 0, 'unexercisedValue': 780281}, {'maxAge': 1, 'name': 'Ms. Stacy A. Coen M.B.A.', 'age': 52, 'title': 'Senior VP & Chief Business Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 584042, 'exercisedValue': 0, 'unexercisedValue': 10100}, {'maxAge': 1, 'name': 'Dr. Michael J. Vasconcelles M.D., Ph.D.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 304620, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lauren A. White M.B.A.', 'age': 44, 'title': 'Senior VP & Chief Financial Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Anabel  Chan', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel S. Char J.D.', 'age': 61, 'title': 'Senior VP, Chief Legal Officer & Secretary', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Ms. Courtney  O'Konek", 'title': 'Senior Director of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Audrey  Bergan', 'title': 'Senior VP & Chief HR Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Theresa G. Wingrove', 'age': 65, 'title': 'Senior Vice President of Regulatory Affairs & Quality', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 548205, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Isabel  Kalofonos', 'title': 'Senior VP & Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§7
shareHolderRightsRisk§5
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.154
priceToSalesTrailing12Months§28.798477
currency§USD
dateShortInterest§1702598400
forwardEps§0.38
exchange§NMS
quoteType§EQUITY
shortName§ImmunoGen, Inc.
longName§ImmunoGen, Inc.
firstTradeDateEpochUtc§627316200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§133c6781-87f8-396c-aba6-e5872f74f481
gmtOffSetMilliseconds§-18000000
targetHighPrice§53.0
targetLowPrice§16.0
targetMeanPrice§31.06
targetMedianPrice§31.0
recommendationMean§2.8
recommendationKey§hold
numberOfAnalystOpinions§12
quickRatio§5.515
grossMargins§0.26423
ebitdaMargins§-0.27278998
trailingPegRatio§None
